[Rebamipide].
Shimoyama
Tadashi
T
First Department of Internal Medicine, Hirosaki University.
Fukuda
Shinsaku
S
Liu
Qiang
Q
Sugawara
Kazuo
K
D000409:Alanine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000494:pharmacology / Q000627:therapeutic use; D000975:Antioxidants; D016207:Cytokines / Q000378:metabolism; D004359:Drug Therapy, Combination; D005753:Gastric Mucosa / Q000378:metabolism; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy; D016480:Helicobacter pylori / Q000201:enzymology; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D018375:Neutrophil Activation / Q000187:drug effects; D018384:Oxidative Stress / Q000187:drug effects; D010437:Peptic Ulcer / Q000188:drug therapy / Q000209:etiology; D015363:Quinolones / Q000494:pharmacology / Q000627:therapeutic use; D014510:Urease / Q000037:antagonists & inhibitors
D000897:Anti-Ulcer Agents; D000975:Antioxidants; D016207:Cytokines; D018836:Inflammation Mediators; D015363:Quinolones; D014510:Urease; C052785:rebamipide; D000409:Alanine